Q-omics provides the consensus-scored ZNF577 profile across patient tissues and cancer cell-line models. ZNF577 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, ZNF577 is differentially expressed in 12, with the highest sampling consensus in KICH. Additionally, ZNF577 RNA expression shows 19,961 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight HNSC, KICH, and GBM as cancer lineages where ZNF577 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF577 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF577 survival associations across molecular data types. ZNF577 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF577 RNA expression–survival associations across cancer types. High ZNF577 expression shows unfavorable associations in LGG, but favorable associations in HNSC, BLCA, SCLC, KIRC and READ. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for ZNF577 RNA expression.
This table summarizes ZNF577 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF577. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF577 shows lower tumor expression in KICH, KIRC, KIRP, BRCA, THCA and LUSC. The KICH box plot shows higher ZNF577 RNA expression in normal versus tumor tissue (log2 FC = −1.652, t-test p < 0.001).
This table shows molecular features associated with ZNF577 in patient tissues and cancer cell lines. In patient samples, ZNF577 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF577 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
